Please assess the completion status of the following clinical trial:

Trial Title: Uterotonic Prophylaxis Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 20 wks 0 days gestation and 24 wks 0 days gestation~* English or Spanish speaking~* BP before injection 140/90 or below~* 18 years old or over~Exclusion criteria:~* hypertension either on the preoperative or operative day (defined as systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg)~* D\&E procedures with more than one day of cervical preparation with dilators~* use of protease inhibitors~* known coagulopathy~* known morbidly adherent placenta

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- methergine (Type: EXPERIMENTAL): Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
- saline placebo (Type: PLACEBO_COMPARATOR): Placebo group saline single injection when manual cervical dilation begins the day before the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).